JP2018517415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517415A5 JP2018517415A5 JP2017564059A JP2017564059A JP2018517415A5 JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5 JP 2017564059 A JP2017564059 A JP 2017564059A JP 2017564059 A JP2017564059 A JP 2017564059A JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cell
- cells
- receptor
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 99
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 32
- 108010087819 Fc receptors Proteins 0.000 claims description 30
- 102000009109 Fc receptors Human genes 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 12
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 12
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 12
- -1 CSPG-4 Proteins 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 229960000548 alemtuzumab Drugs 0.000 claims description 6
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 6
- 229960000578 gemtuzumab Drugs 0.000 claims description 6
- 229960000575 trastuzumab Drugs 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 102100027285 Fanconi anemia group B protein Human genes 0.000 claims description 4
- 108700011146 GPA 7 Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 4
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102100022496 Mucin-5AC Human genes 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229960003008 blinatumomab Drugs 0.000 claims description 4
- 229940126590 dalatumumab Drugs 0.000 claims description 4
- 229960004137 elotuzumab Drugs 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000026725 cyclothymic disease Diseases 0.000 claims description 2
- 229960002204 daratumumab Drugs 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000001990 intravenous administration Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021036808A JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A JP2023054220A (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173701P | 2015-06-10 | 2015-06-10 | |
| US62/173,701 | 2015-06-10 | ||
| US201662337044P | 2016-05-16 | 2016-05-16 | |
| US62/337,044 | 2016-05-16 | ||
| PCT/US2016/036991 WO2016201304A1 (en) | 2015-06-10 | 2016-06-10 | Modified nk-92 cells for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Division JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517415A JP2018517415A (ja) | 2018-07-05 |
| JP2018517415A5 true JP2018517415A5 (enExample) | 2019-06-27 |
Family
ID=57504144
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564059A Pending JP2018517415A (ja) | 2015-06-10 | 2016-06-10 | がんを処置するための改変ｎｋ−９２細胞 |
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A Pending JP2023054220A (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A Pending JP2023054220A (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10738279B2 (enExample) |
| EP (3) | EP4272757A3 (enExample) |
| JP (4) | JP2018517415A (enExample) |
| KR (4) | KR20240013282A (enExample) |
| CN (2) | CN107709552B (enExample) |
| AU (1) | AU2016275030B2 (enExample) |
| CA (1) | CA2987290C (enExample) |
| ES (1) | ES2958720T3 (enExample) |
| IL (2) | IL255884B2 (enExample) |
| WO (1) | WO2016201304A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201608393TA (en) | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| KR20240013282A (ko) | 2015-06-10 | 2024-01-30 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
| US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| US11787848B2 (en) * | 2016-06-08 | 2023-10-17 | Precigen, Inc. | CD33 specific chimeric antigen receptors |
| JP7118072B2 (ja) * | 2017-01-06 | 2022-08-15 | イミュニティーバイオ インコーポレイテッド | Ｃｄ９６／ｔｉｇｉｔ発現が低下した遺伝子改変型ｎｋ－９２細胞 |
| KR20240128814A (ko) * | 2017-01-10 | 2024-08-27 | 프레시전 인코포레이티드 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| WO2018144777A2 (en) * | 2017-02-01 | 2018-08-09 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| JP2020510646A (ja) * | 2017-02-20 | 2020-04-09 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP7098648B2 (ja) | 2017-03-08 | 2022-07-11 | イミュニティーバイオ インコーポレイテッド | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CA3058144A1 (en) * | 2017-03-27 | 2018-10-04 | Nantcell, Inc. | Ank and il-12 compositions and methods |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| MX2019011958A (es) * | 2017-04-05 | 2019-12-11 | Korea Res Inst Bioscience & Biotechnology | Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye. |
| SG10202111394XA (en) * | 2017-04-13 | 2021-12-30 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| AU2018352984B2 (en) | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| US12053490B2 (en) | 2017-10-26 | 2024-08-06 | St. Jude Children's Research Hospital, Inc. | Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells |
| US20210187024A1 (en) * | 2017-11-01 | 2021-06-24 | Nantkwest, Inc. | NK-92 Cells to Stimulate Anti-Cancer Vaccine |
| WO2019101998A1 (en) | 2017-11-24 | 2019-05-31 | Onkimmune Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
| CN110028589B (zh) * | 2018-02-07 | 2023-07-21 | 阿思科力(苏州)生物科技有限公司 | 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用 |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| CN112004829A (zh) * | 2018-03-12 | 2020-11-27 | 南克维斯特公司 | Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途 |
| WO2019182425A1 (ko) * | 2018-03-23 | 2019-09-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| IL321548A (en) | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| IL296050B2 (en) * | 2018-08-01 | 2024-12-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| EP3746547A4 (en) * | 2018-10-31 | 2021-12-01 | Nantkwest, Inc. | ELIMINATION OF POSITIVE MALIGNITIES FOR PD-L1 BY NK CELLS EXPRESSING A PD-L1 CHEMERIC ANTIGEN RECEPTOR |
| WO2020091869A1 (en) * | 2018-10-31 | 2020-05-07 | Nantkwest, Inc. | Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells |
| US12109238B2 (en) | 2018-11-06 | 2024-10-08 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| CA3092305A1 (en) * | 2018-11-06 | 2020-05-14 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells |
| US20220017594A1 (en) * | 2018-11-26 | 2022-01-20 | Nantkwest, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| CN113811603B (zh) * | 2019-03-15 | 2024-08-16 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| JP7555392B2 (ja) * | 2019-07-26 | 2024-09-24 | ナントクウェスト，インコーポレーテッド | 腫瘍溶解のための有効な治療用製剤としての、抗体を予め負荷したｃｄ１６＋ｎｋ－９２細胞 |
| AU2019459423B2 (en) * | 2019-08-01 | 2023-06-01 | Immunitybio, Inc. | Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells |
| WO2021054789A1 (ko) * | 2019-09-18 | 2021-03-25 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| US20210106619A1 (en) * | 2019-10-10 | 2021-04-15 | Nantkwest, Inc. | NK-92 Bone and Brain targeting |
| EP4061385A4 (en) * | 2019-11-19 | 2024-08-14 | Acibadem Mehmet Ali Aydinlar Üniversitesi | METHOD FOR REDESIGNING AND EXPANDING NK92 CELLS FOR USE IN IMMUNOTHERAPY |
| WO2021100001A1 (en) * | 2019-11-20 | 2021-05-27 | Nantkwest, Inc. | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
| CN113646435A (zh) * | 2019-12-09 | 2021-11-12 | 南克维斯特公司 | 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆 |
| EP4097219A4 (en) * | 2020-01-28 | 2023-10-11 | ImmunityBio, Inc. | CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| CN115397973A (zh) * | 2020-01-30 | 2022-11-25 | 免疫生物公司 | 表达car的nk细胞消除bcma阳性恶性肿瘤 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| CA3176258A1 (en) * | 2020-03-28 | 2021-10-07 | Board Of Regents, The University Of Texas System | Cell immunotherapy for the treatment of cancer |
| TW202216776A (zh) | 2020-07-07 | 2022-05-01 | 美商康愈有限責任公司 | Mic抗體及結合劑以及其使用方法 |
| CN117136232A (zh) * | 2020-10-26 | 2023-11-28 | 全国儿童医院研究所 | 嵌合抗原受体（car）nk细胞及其用途 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| WO2024236557A1 (en) | 2023-05-12 | 2024-11-21 | Gilboa Therapeutics LTD | Compositions comprising an fc domain for the treatment of medical conditions |
| WO2025158400A1 (en) * | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| EP1007630B1 (en) | 1997-04-30 | 2006-04-19 | Hans Klingemann | Natural killer cell lines and methods of use |
| AU743066B2 (en) | 1997-11-06 | 2002-01-17 | Roche Diagnostics Gmbh | Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| WO2000020460A1 (en) | 1998-10-05 | 2000-04-13 | Ludwig Institute For Cancer Research | Methods for producing human tumor antigen specific antibodies |
| US7098008B2 (en) | 2000-04-25 | 2006-08-29 | Ic&G Do. Ltd. | Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use |
| SE526227C2 (sv) * | 2002-05-15 | 2005-08-02 | North China Pharmaceutical Group | Metod för rening av rekombinant humant serumalbumin |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| WO2006004518A1 (en) | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| US7618817B2 (en) * | 2004-07-10 | 2009-11-17 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| JP5299902B2 (ja) * | 2007-01-30 | 2013-09-25 | 中外製薬株式会社 | キメラＦｃγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法 |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| EP3327035A1 (en) | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
| US9212229B2 (en) * | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2765193B1 (en) | 2011-10-07 | 2017-08-09 | Mie University | Chimeric antigen receptor |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| RU2729401C2 (ru) * | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| JP6420776B2 (ja) * | 2013-03-05 | 2018-11-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫療法のためのエンゲージャー細胞 |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| BR112015027567B1 (pt) | 2013-05-03 | 2024-02-20 | Ohio State Innovation Foundation | Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula |
| CN104561069A (zh) * | 2013-10-23 | 2015-04-29 | 深圳先进技术研究院 | 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| ES2935906T3 (es) * | 2013-11-01 | 2023-03-13 | Immunitybio Inc | Composiciones y métodos tumoricidas y antimicrobianos |
| WO2015075468A1 (en) * | 2013-11-21 | 2015-05-28 | Ucl Business Plc | Cell |
| KR20240013282A (ko) * | 2015-06-10 | 2024-01-30 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
| WO2020091869A1 (en) * | 2018-10-31 | 2020-05-07 | Nantkwest, Inc. | Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells |
-
2016
- 2016-06-10 KR KR1020247001893A patent/KR20240013282A/ko not_active Ceased
- 2016-06-10 KR KR1020257004508A patent/KR20250027585A/ko active Pending
- 2016-06-10 IL IL255884A patent/IL255884B2/en unknown
- 2016-06-10 CN CN201680033667.9A patent/CN107709552B/zh active Active
- 2016-06-10 AU AU2016275030A patent/AU2016275030B2/en active Active
- 2016-06-10 CN CN202110790574.3A patent/CN113502270B/zh active Active
- 2016-06-10 EP EP23176181.8A patent/EP4272757A3/en active Pending
- 2016-06-10 IL IL309167A patent/IL309167A/en unknown
- 2016-06-10 EP EP24185893.5A patent/EP4424326A3/en active Pending
- 2016-06-10 CA CA2987290A patent/CA2987290C/en active Active
- 2016-06-10 KR KR1020187000382A patent/KR102526538B1/ko active Active
- 2016-06-10 WO PCT/US2016/036991 patent/WO2016201304A1/en not_active Ceased
- 2016-06-10 KR KR1020237013832A patent/KR102627811B1/ko active Active
- 2016-06-10 JP JP2017564059A patent/JP2018517415A/ja active Pending
- 2016-06-10 EP EP16808427.5A patent/EP3307876B1/en active Active
- 2016-06-10 US US15/531,109 patent/US10738279B2/en active Active
- 2016-06-10 ES ES16808427T patent/ES2958720T3/es active Active
-
2020
- 2020-07-27 US US16/940,018 patent/US11788059B2/en active Active
-
2021
- 2021-03-09 JP JP2021036808A patent/JP7275178B2/ja active Active
-
2023
- 2023-02-22 JP JP2023025723A patent/JP2023054220A/ja active Pending
- 2023-09-07 US US18/463,213 patent/US20240002802A1/en active Pending
-
2025
- 2025-03-24 JP JP2025048124A patent/JP2025089426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517415A5 (enExample) | ||
| Roberts et al. | Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL | |
| JP2024099850A5 (enExample) | ||
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| JP2018510881A5 (enExample) | ||
| JP2020509767A5 (enExample) | ||
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| JP2017537972A5 (enExample) | ||
| JP2022159548A5 (enExample) | ||
| JP2021137024A (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| Tay et al. | TriKEs and BiKEs join CARs on the cancer immunotherapy highway | |
| JP2016520074A5 (enExample) | ||
| Shevtsov et al. | Immunological and translational aspects of NK cell-based antitumor immunotherapies | |
| Shi et al. | Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects | |
| JP2020516654A5 (enExample) | ||
| JP2020530989A5 (enExample) | ||
| JP2021508255A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| MX2011012047A (es) | Inmunoglobulinas humanas anti-cd52. | |
| JP2012254083A5 (enExample) | ||
| JP2017515460A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2014518615A5 (enExample) |